Research Analysts Set Expectations for BMRN Q1 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Analysts at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a research note issued on Wednesday, January 8th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will earn $0.61 per share for the quarter, up from their previous forecast of $0.60. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.49 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s FY2025 earnings at $2.68 EPS, Q2 2026 earnings at $0.84 EPS and Q3 2026 earnings at $0.89 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.78 by ($0.23). BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. The business had revenue of $746.00 million during the quarter, compared to the consensus estimate of $703.37 million. During the same period in the prior year, the company earned $0.26 earnings per share. The business’s revenue was up 28.4% on a year-over-year basis.

Several other research firms also recently issued reports on BMRN. JPMorgan Chase & Co. dropped their target price on BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 30th. Wedbush upgraded BioMarin Pharmaceutical to a “strong-buy” rating in a research report on Monday, November 4th. Scotiabank lowered their price target on BioMarin Pharmaceutical from $95.00 to $78.00 and set a “sector perform” rating on the stock in a research report on Tuesday, September 17th. Truist Financial reduced their price objective on BioMarin Pharmaceutical from $118.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, September 17th. Finally, William Blair cut BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 30th. Seven research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $94.20.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $67.38 on Friday. The firm has a market cap of $12.84 billion, a price-to-earnings ratio of 40.35, a price-to-earnings-growth ratio of 0.65 and a beta of 0.29. The stock has a fifty day simple moving average of $65.83 and a two-hundred day simple moving average of $75.04. BioMarin Pharmaceutical has a 1-year low of $61.15 and a 1-year high of $96.64. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of hedge funds have recently modified their holdings of the business. nVerses Capital LLC purchased a new stake in BioMarin Pharmaceutical in the 3rd quarter worth $28,000. BOKF NA bought a new position in BioMarin Pharmaceutical during the 2nd quarter valued at about $31,000. TD Private Client Wealth LLC grew its holdings in BioMarin Pharmaceutical by 57.4% during the 3rd quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 186 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in BioMarin Pharmaceutical in the 2nd quarter worth about $47,000. Finally, Meeder Asset Management Inc. grew its stake in BioMarin Pharmaceutical by 920.8% in the 3rd quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 663 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Charles Greg Guyer sold 5,278 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total transaction of $350,300.86. Following the completion of the sale, the executive vice president now owns 68,909 shares of the company’s stock, valued at $4,573,490.33. The trade was a 7.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.85% of the stock is currently owned by insiders.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.